Abstract 1330P
Background
Health Technology Agencies improve their assessment over time. In 2020, the French HAS published an Organizational Impact map, to define and structure organizational impact (OI) for health technologies. As immunotherapies have extended survival and improved quality of life in advanced cancer, we identified OIs that immunotherapies had on health care system and professionals.
Methods
A literature review was conducted to identify the OI induced by immunotherapies and the actors concerned. Then, interviews with various healthcare stakeholders (HS) were performed. They were asked if immunotherapies had OI classified into 3 macrocriteria: impact on care process (6 criteria), impact on capacities and skills required by the actors (6 criteria) and impact on society (4 criteria). If an OI was mentioned for a criterion, details regarding its impact (minor, moderate, major) and its period (learning and/or routine) were asked. We considered that an OI exists when 75% of HS mentioned an impact for a given criterion.
Results
Overall, 27 HS were interviewed. For 12 out of the 16 criteria, the majority of HS mentioned an impact while literature enabled to identify impacts for 11 criteria. Three criteria (HS skills, transferred skills between HS, scheduling capabilities) had consensus among HS and high impact; 3 criteria (rhythm or care duration, working/living conditions, social relationship) showed consensus but moderate impact; 2 criteria (funding, scheduling capabilities cross-structure) had high impact but no consensus. For 8 criteria (environment, health security, inequity…) no consensus and moderate impact was found.
Conclusions
The introduction of immunotherapies for advanced cancer has an important OI in France, regarding capacities and skills. Qualitative analysis of interviews will provide more information regarding all HS perspectives and OI needing further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
I. Borget: Financial Interests, Personal, Invited Speaker: Novartis, Allergan, Roche, Astellas, AstraZeneca; Financial Interests, Personal, Advisory Board: Gilead, BMS. C. Chouaid: Financial Interests, Personal, Advisory Board: AstraZeneca, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AstraZeneca, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. F. Cotté: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. A. Gaudin: Financial Interests, Personal, Full or part-time Employment, Employee: Bristol Myers Squibb. V. Grumberg: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb.